Sjögren’s Syndrome Therapeutics Exhibit Promising Pipeline with approximately 42 drug candidates

The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates, of which 29 drug candidates are in active stage. Among the active drug candidates, three are in Phase III stage, 10 are in Phase II stage, seven are in Phase I stage and nine are in Pre-Clinical stage. The development of 11 Sjögren’s syndrome drug candidates is found to be inactive and two drug candidates are discontinued.

Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

The research found that different companies have collaborated for the development of Sjögren’s syndrome. One of the collaborations occurred in December 2014, between Aldeyra Therapeutics, Inc. and the National Organization for Rare Disorders (NORD), a non-profit organization that helps people with rare diseases, was focused towards increasing awareness among patients suffering Sjögren-Larsson syndrome. The collaboration occurred to provide patients with opportunities to connect with each other and access information about their Sjögren-Larsson syndrome, available resources and efforts related to diagnosis and treatment.

Some of the key players of Sjögren syndrome pipeline include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company, Novartis AG, Aldeyra Therapeutics, Inc., GlaxoSmithKline plc, Amgen Inc., F. Hoffmann-La Roche AG and Biogen, Inc.

News Courtesy: P&S Market Research

The Pipeline of Drugs for Treating Candidiasis is Anticipated to Boost in Future

The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates, of which two drug candidates are in Phase III stage of development, while five drug candidates are in Phase II stage, one drug candidate is in Phase I stage, 10 drug candidates are in Pre-Clinical stage and four drug candidates are in the Discovery stage. Candidiasis is a common type of fungal infection caused by fungus known as candida. Candida is found in various parts of human body including mouth, skin or belly and is non-infectious until it gets right environment to multiply and grow uncontrollably. This result in occurring of the infection, known as candidiasis.

As per the findings of the research, around 27.0% drug candidates of candidiasis pipeline are being developed to be administered by oral route, 9.0% by topical route and 27.0% are to be administered by other routes, which includes intravenous, inhalation and intramuscular. Route of administration of around 37.0% drug candidates of candidiasis pipeline was not disclosed.

The research also found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia. In January 2016, USFDA granted both fast track and qualified infectious disease product (QIDP) designations for the intravenous formulation of SCY-078 for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.

Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., Viamet Pharmaceuticals, Inc., NovaDigm Therapeutics, Inc., iCo Therapeutics, Inc., NovaBiotics Ltd., Bionex Pharmaceuticals LLC, Wellstat Therapeutics Corporation, Sealife Pharma GmbH and TGV-inhalonix.

News Courtesy: P&S Market Research

Dry Eye Syndrome Exhibits Significant Growth in Pipeline with Maximum Drug Candidates in Pre-Clinical Stage

Dry Eye Syndrome Therapeutics Pipeline Analysis

The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates, of which 11 drug candidates are in Phase III stage of development, 16 drug candidates are in Phase II stage of development, five drug candidates are in Phase I stage, while 17 drug candidates are in Pre-Clinical stage and one drug candidate in the Discovery stage of development. Dry eye syndrome is also known as keratoconjunctivitis sicca or keratitis sicca. The disease is caused by a chronic lack of sufficient moisture and lubrication on the ocular surface of the eye. Some of the major consequences of dry eyes include constant eye irritation, significant inflammation and scarring of the front surface of the eye.

According to the research findings, around 78.0% drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route and 4.0% are to be administered by other routes, that include oral and intracanalicular. Route of administration of around 18.0% drug candidates of dry eye syndrome pipeline has not been not disclosed.

InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of ISV-101 for the treatment of dry eye syndrome. The technology platform delivers a wide variety of potential drug agents. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix. The topical ophthalmic solution is a gel forming drop, that extends the time for which the drug stays inside the eye, relative to the conventional eye drops.

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd., Laboratoires Thea, Avizorex Pharma, S.L., Sylentis, S.A.U., RegeneRx Biopharmaceuticals, Inc., Mitotech, SA, Seikagaku Corporation, KPI Therapeutics Inc. and Xigen SA.

News Courtesy: P&S Market Research

Military Helicopter Contributes Largest Revenue to the Global Helicopter Market

Helicopter Market

According to the study, the global helicopter market is likely to grow at a CAGR of 3.4% during 2017 – 2023. Technological advancements, ageing helicopter fleet, and increasing usage of helicopters in disaster relief are driving the global helicopter market. The market is further expected to gain revenue due to the increasing customer compliance for more equipped and sophisticated avionics and flight safety. Although, there has been a drop in the number of new fleet during 2013 – 2016, increased demand from developing nations would create ample opportunities for the global helicopter manufacturers.

As per the findings of research, military helicopter held the larger share in the global helicopter market in 2016, primarily due to high value to volume ratio and increased demand from emerging economies in Asia-Pacific and increased need for advanced defense equipment. Civil helicopters market is expected to witness higher growth during 2017 – 2023. The highest growth of civil helicopter is attributed to the increasing demand in law enforcement, tourism, medical services, general utility and firefighting. However, the ongoing crisis in the oil and gas industry may lead to slower adoption of new fleet, especially large and heavy helicopters.

Geographically, North America has been the largest market for helicopter, with the U.S. being the larger contributor to the regional market, compared to Canada. Retirement of old generation helicopters is expected to create opportunities for the North American helicopter market. Majority of operators in North America are planning to increase the use of helicopters, especially civil helicopters; leading to a steady growth of the market in the region. The emerging economies of Latin America and Asia-Pacific, especially Brazil, China and India, are expected to witness high demand for civil helicopters for various applications such as law enforcement, tourism, medical services, general utility and firefighting. Latin American civil helicopter market is expected to witness the highest growth during 2017 – 2023.

Some of the other key players in the market include Bell Helicopter Textron Inc., Korea Aerospace Industries, Ltd., Airbus SE, Russian Helicopters, Leonardo S.p.A., The Boeing Company, Lockheed Martin Corporation, Robinson Helicopter Company, Hindustan Aeronautics Limited, MD Helicopters, Inc., and Kaman Corporation.

News Courtesy: P&S Market Research

Defense Sector Contributes Largest Revenue to the Global Armored Vehicles Market

Armored Vehicles Market

The global market for armored vehicles is likely to grow from USD24.8 billion in 2016 to USD36.6 billion by 2023. With increasing security concerns in the Asia-Pacific region and rising political disputes across the globe, the demand for armored vehicles is expected to gain traction during the forecast period. The increasing demand for light or medium-sized armored vehicles for combat operations has resulted in the widespread adoption of wheeled-type armored vehicles. This is expected to further propel the demand for armored vehicles during the forecast period.

As per the findings of research, the defense sector emanated the largest demand for armored vehicles. The segment is expected to exhibit similar trends during the forecast period. Active mine system is the largest segment in armored vehicles market, by technology; while active protection system is expected to exhibit the fastest growth in the global armored vehicles market, by technology. Military emanates the maximum demand in the global defense armored vehicles market, by application; while government is expected to dominate the global commercial armored vehicles market, by application. Infantry fighting vehicles is expected to be the largest segment in the global defense armored vehicles market, by product; while SUV is most commonly-used armored vehicle in the commercial sector.

Some of the key players in the global armored vehicles market include General Dynamics Corporation, Lockheed Martin Corporation, BAE Systems plc, Elbit Systems Ltd., Oshkosh Corporation, Textron Inc., International Armored Group (IAG), Denel Land Systems, Rheinmetall AG, Thales Group and INKAS Armored Vehicle Manufacturing.

Product launches and strategic expansion plans by key players have been the major recent developments in the global armored vehicles market. Companies are increasingly investing in R&D activities and focusing on strategic partnerships and contracts to strengthen their market presence across the globe.

News Courtesy: P&S Market Research

Glass Run Channel and Waist Belt Seals Contribute Largest Revenue to the Global Automotive Window and Sealing Systems Market

Automotive Window and Sealing Systems Market

As per the research, the global automotive window and sealing systems market high is likely to grow from $17,064.0 million in 2016 to $29,515.0 million by 2023. The rapidly growing automotive industry especially in emerging economies of Asia-Pacific, Africa and Latin America is generating significant demand for automotive sealing systems.

The automotive window and sealing systems market include products such as glass run channel, door seals, front and real windshield seals, and others exterior seals. These products are mainly manufactured using ethylene propylene diene monomer (EPDM) as the raw material; however, as the technology has developed, thermoplastic elastomers find their use as raw materials. The developing economies such as India and China use EPDM as raw materials. Whereas the technologically-advance markets such as U.S. and Germany, use Thermoplastic Elastomers (TPEs) as raw material for exterior sealing systems. The new technology is likely to be adopted in developed countries during the forecast period.

The research states that the global automotive window and sealing systems market had a consolidated structure in 2015, where the market is dominated by organized players. Some of the key players in the global automotive window and sealing systems market include Cooper Standard Inc., Hutchinson Automotive, Magna International, Sumitomo Chemical Co. Ltd., Toyoda Gosei Co. Ltd., Minth Group, and Henniges Automotive Holdings Inc.

Acquisition and strategic partnerships have been the major recent developments in the global automotive window and sealing systems. For instance, in September 2016, Hutchinson acquired the French company Composite Industrie based in Bondoufle, Paris. The company has a production unit in Casablanca, Morocco and is specialized in designing, qualifying and producing composite products serving the aerospace and defense markets. Additionally, In May 2016, Henniges Automotive Holdings, Inc., expanded its partnership with Burkool S.A., a sealing solutions manufacturer based in Buenos Aires, Argentina, to meet the growing demand of the automotive original equipment manufacturers (OEMs) in Brazil.

News Courtesy: P&S Market Research

Global Closed Loop Stepper Motor Market Size, Share, Development, Growth and Demand Forecast to 2023

The global closed loop stepper motor market is projected to grow at a CAGR of 6.3% during 2017 – 2023. Traditional stepper motors are considered as open-loop steppers, owing to the absence of a feedback mechanism. These systems do not have the capability to corroborate that the target position has been achieved. Unlike traditional steppers, closed loop systems, with inherent encoders constantly communicate back to the controller and also make the required adjustments to achieve the target position.

Global closed loop stepper motor market is expected to show steady growth through 2023. Major factors propelling the growth of the global closed loop stepper motor market include rapid growth in automation, standardization of energy efficiency, integration of motion control components and low pricing as compared to servo motors. However, it is difficult to operate closed loop stepper systems at higher speed, which is a major factor restraining the growth of its market across the globe.

The major trends observed in the global closed loop stepper motor market include imposition of regulations on energy efficiency and evolution of micro-stepping technology. These energy regulations have majorly been formulated by global warming and for raising ecological environments, globally. Moreover, the evolution of industry 4.0 is expected to offer enormous opportunities, facilitating growth in the global closed loop stepper motor market.

Closed loop stepper motors are widely used in several aspects, for the purpose of providing automation. Packaging and labelling, industrial machineries, medical equipment and semiconductors are some of the major end-users of closed loop stepper systems. Technology advancement and brisk growth in automation are likely to propel the global closed loop stepper motor market growth, over next few years. Moreover, internet of things (IoT), engineering services and system integration are likely to accompany expansion of automation into other markets as well. The global closed loop stepper motor market is expected to register a steady growth owing to the evolution of fourth industrial revolution (also termed as industry 4.0) and the surge in demand of automation.

Global warming, surging energy costs and booming eco-friendly alertness have led to the standardization of energy efficiency, owing to which governments and manufacturing companies are keeping energy efficient manufacturing on the top of their agenda and are looking for the most adequate measures to raise energy efficiency levels in all the processes. For example, in 2014, American National Standard Institute (ANSI) Energy Efficiency Standardization Coordination Collaborative (EESCC) published a set of decisive instructions portraying the standards and obedience assessment curriculum required to enable a more energy efficient environment.

Get More Information Visit: P&S Market Research

Consumable Segment Contributes Largest Revenue to the Global HIV Diagnosis Market

HIV Diagnosis Market

According to the study, the global HIV diagnosis market is likely to grow significantly during the forecast period, due to rising prevalence of HIV/AIDS, increasing awareness with respect to blood donations and blood transfusions, and advantageous features of point of care instruments and kits are some of the key drivers for the global market growth. In addition, rising healthcare expenditure leading to improvement in healthcare infrastructure further contributes to the growth of the overall market. High cost of automated procedure and stringent regulatory requirements are some of the key factors restraining the global market growth.

As per the findings of the research, based on products, consumable is the largest product category, in the global market. Antibody test has been the largely performed test of the global market, followed by viral load, CD4, early infant diagnosis and viral identification. Diagnostic laboratories have been the largest end user of HIV diagnosis, followed by hospitals, research institutes and others.

Geographically, North America has been the largest market for HIV diagnosis, with the U.S. being the largest contributor to the regional market. Increasing prevalence of HIV/AIDS and advantageous features of point of care instruments and kits has been driving the growth of the North American market. In Europe, the U.K. has been the largest contributor to the market for HIV diagnosis, followed by Germany and France. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 – 2023, owing to increasing cases of HIV rising healthcare expenditure and increasing blood transfusion.

Some of the key players in the global HIV diagnosis market include Siemens AG, Hoffman La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories and Hologic Inc.

News Courtesy: P&S Market Research

Computed Tomography Segment Contributes Largest Revenue to the Global Image Guided Surgery Devices Market

Image Guided Surgery Devices Market Analysis

According to the study, the global image guided surgery devices market is likely to grow significantly during the forecast period, due to increasing prevalence of chronic diseases, and cancer, rising geriatric population and increasing cases of neurological disorders. In addition to these factors, rising healthcare expenditure and technological advancements in medical imaging also contributes to the growth of the overall market. High cost of imaging techniques and stringent regulatory requirements are some of the key factors restraining the global market growth.

As per the findings of the research, the CT is the largest segment, based on device type, in the global image guided surgery devices market. CT is a non-invasive, accurate and fast diagnostic imaging test. It uses x-ray equipment to produce 3D images by taking series of images from different angles. Each image created during the CT procedure shows the bones, tissues and organs in a thin “slice” of the body.

It provides cross-sectional images generated during the CT scan and can be reformatted in multiple planes. It is used for diagnosing skeletal abnormalities, blood clots, blood vessel aneurysm and cancer. Neurology has been the largest application area for image guided surgery devices, followed by orthopedic surgery, ENT surgery, oncology surgery and others.

Geographically, North America has been the largest market for image guided surgery devices, with the U.S. being the larger contributor to the regional market. Increasing prevalence of neurological disorders, rising geriatric population and adoption of technological advanced imaging techniques are some of the factors that have been driving the growth of the North America image guided surgery devices market. The U.K. has been the largest contributor to the European market for image guided surgery devices, followed by Germany and France. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 – 2023, owing to increasing cases of cancer, arthritis, neurological disorders and rising geriatric population.

Some of the key players in the global image guided surgery devices market include Siemens AG, GE Healthcare, Koninklijke Philips N.V., Canon Inc., Hitachi, Ltd., KARL STORZ GmbH & Co. KG., Medtronic, Inc., St. Jude Medical, Inc., Varian Medical Systems, Inc., Smith & Nephew plc, Integra LifeSciences Corporation and Zimmer Holdings, Inc.

News Courtesy: P&S Market Research

Prefilled Auto-Injectors Contribute Largest Revenue to the Global Auto-Injectors Market

Auto-Injectors Market

According to the study, the global auto-injectors market is likely to grow significantly during the forecast period, due to increasing prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising geriatric population and high production of biologics. Additionally, increasing healthcare spending and various beneficial features of auto-injectors also contribute to the growth of the overall market. However, high cost of auto-injectors and stringent regulatory requirements are some of the key factors restraining the growth of global auto-injectors market.

Insights on market segments

As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.

North America stands as the largest auto-injectors market

Geographically, North America has been the largest market for auto-injectors, with the U.S. being the larger contributor to the regional market, compared to Canada. Increasing cases with diabetes and anaphylaxis, rising geriatric population, and increasing production of biologics are some of the factors that have been driving the growth of the North American auto-injectors market. North America is expected to contribute over 67.0% to the global auto-injectors market by 2023. The U.K. has been the largest contributor to the European auto-injectors market, followed by Germany and France. The auto-injectors market is expected to witness the fastest growth in Asia-Pacific during 2017 – 2023, owing to increasing cases of anaphylaxis, increasing awareness about needle-stick injuries, increasing healthcare expenditure, and growing geriatric population.

Key players in the market are collaborating to offer advanced auto-injectors

Key companies in the auto-injectors market is collaborating to offer advanced auto-injectors. In March 2017, Mylan N.V. entered in a global settlement and license agreement with Genentech Inc and Roche Holding AG in relation to patents for Herceptin (trastuzumab), which provides Mylan N.V. with global licenses for its trastuzumab product. This is expected to help Mylan N.V. to commercialize trastuzumab globally, except in Japan, Brazil and Mexico.

Some of the key players operating in the global auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.

News Courtesy: P&S Market Research